The historical rank and industry rank for Sarepta Therapeutics's Net Margin % or its related term are showing as below:
LTS:0L35'
s Net Margin % Range Over the Past 10 Years
Min: -4930.18 Med: -67.53 Max: 12.37
Current: 2.98
LTS:0L35's Net Margin % is ranked better than 73.89% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs LTS:0L35: 2.98
Sarepta Therapeutics (LTS:0L35) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sarepta Therapeutics Net Margin % Related Terms
Sarepta Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0L35 vs ABCL, RAPP, RXRX: Net Margin % Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (LTS:0L35) has a Net Margin % of 45.29% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sarepta Therapeutics and its competitors. According to the industry distribution chart, Sarepta Therapeutics ranks #247 out of 946 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Sarepta Therapeutics' Net Margin % too high?
Sarepta Therapeutics' current Net Margin % is 45.29%. Based on the distribution chart, Sarepta Therapeutics ranks #247 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sarepta Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Net Margin % compare to ABCL and RAPP?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #247 out of 946 companies for Net Margin %. This puts Sarepta Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Net Margin % is 45.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $128.15, compared to a current price of $16.10 — trading 87.4% below its estimated fair value. The current Net Margin % is 45.29%. Sarepta Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Net Margin % is 45.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $16.10 is trading 87.4% below its estimated GF Value™ of $128.15.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Net Margin %: 45.29%
GF Value™: $128.15 vs. price of $16.10 (87.4% below fair value)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score
Get the complete analysis for LTS:0L35
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
